in August 2024 – a facility focused on developing novel RNA-based and DNA-based medicine. MASH is a form of non-alcoholic liver disease, which describes a spectrum of conditions like steatosis ...
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...